Developer docs
API playgroundTry for free, no card

Search company profiles

SageMedic

Full company profile

uuid0006bpk

Namestring
SageMedic
Legal namestring
SageMedic Corp.
Websiteurl
sagemedic.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

SageMedic Corp. is a Redwood City, California-based CLIA-certified clinical laboratory (CLIA ID: 05D2236809, accredited by COLA and CMS) that develops and commercializes the SAGE Oncotest™, an ex-vivo functional profiling assay for solid tumor treatment decision support. The test processes fresh cancer tissue into multiple testable replicates within 24 hours and exposes those replicates to a curated panel of FDA-approved drugs, then returns laboratory drug response and resistance results to the ordering oncologist within 7-10 days. The company was founded in 2018 by Dr. Chris Apfel (CEO) and Dr. Brigitte Apfel (Co-Founder, Treasurer), both California-licensed physicians, and operates with 1-10 employees.

The product is positioned as a complement to genomic testing: whereas DNA sequencing identifies mutations, the SAGE Oncotest measures how the patient's actual tumor tissue responds to specific drugs ex-vivo, with internal validation claiming actionable laboratory information in 88% of cases compared to 26.8% for genomic testing and a meta-analysis-based claim that functional profiling makes tumors twice as likely to respond to therapy. The technology builds on published validation studies of predecessor ex-vivo Extreme Drug Resistance (EDR) assays with reported 90%+ negative predictive value. It is indicated for Stage III/IV solid tumors and is not used for early-stage or slow-growing cancers.

SageMedic generates revenue through a one-time, self-pay laboratory service fee per test; the test is not covered by insurance and pricing is not publicly disclosed. Distribution is B2B2C: physicians order the test, fresh tissue is collected at the surgical or biopsy facility and shipped to the California laboratory, and telemedicine consultations are offered only to patients physically in California at the time of service. Specimens are accepted from US physicians nationwide and from international hospitals and physicians, with consent and payment processed via DocuSign under a HIPAA Business Associate Agreement and patient screening handled through Zoho Forms.

Short descriptiontext

SageMedic Corp. operates a CLIA-certified laboratory offering the SAGE Oncotest™, an ex-vivo functional profiling assay that evaluates fresh tumor tissue against FDA-approved drugs to support oncologists' treatment decisions for Stage III/IV solid tumor patients on a self-pay basis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRedwood City, United States
HQ citystring
Redwood City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
functional cancer profiling, precision oncology testing, ex-vivo drug response, tumor resistance profiling, CLIA laboratory services
Industry2 codes
PRIMARYHLAGAEAA
Central Laboratory Services (Core Lab Operations)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Functional Precision Oncology Diagnostics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1SAGE Oncotest Laboratory Testing
TypeOne Time License
Description

One-time laboratory testing service where patients pay for the test directly. The test is not covered by insurance. Physicians order the test, patients sign purchase agreements and pay for the service. Results are delivered within 7-10 days.

sagemedic.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Others
Pricing details1 tier
1Laboratory testing service - pricing not publicly disclosed
ModelOtherBilling cadencePay-as-you-go
Notes

Specific price points are not listed publicly. Test is self-pay only, not covered by insurance.

sagemedic.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1SAGE Oncotest™
Description

Functional profiling assay that evaluates how a patient's tumor tissue responds to FDA-approved drug treatments ex-vivo, providing laboratory insights to support individualized cancer treatment planning within 7-10 days.

sagemedic.com
Core offering1 text field

SageMedic operates a CLIA-certified clinical laboratory offering the SAGE Oncotest™, an ex-vivo functional profiling assay that evaluates fresh cancer tissue samples against a curated panel of FDA-approved drugs to determine drug response and resistance patterns. Results are delivered to the ordering physician within 7-10 days to support individualized oncology treatment planning for patients with advanced solid tumors. Telemedicine consultations are also offered exclusively to patients physically located in California.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 88% actionable information rate vs 26.8% for genomic testing
+3 more records
Product overview1 text field

SageMedic offers a single unified product, the SAGE Oncotest™ functional precision oncology test. This CLIA-certified laboratory service evaluates fresh tumor tissue samples against a curated panel of FDA-approved chemotherapy and targeted therapy drugs using proprietary ex-vivo laboratory techniques. The test is designed to complement genomic testing by providing functional drug response insights, helping oncologists make more informed treatment decisions for patients with advanced solid tumors. Results are delivered within 7-10 days.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Caris offers multi-omic molecular profiling (DNA, RNA, protein) for oncology, including functional and proteomic components, serving oncologists with treatment-decision support — directly comparable to SageMedic's functional profiling service for advanced solid tumors.

TypeDirect peer
Description

Champions provides patient-derived xenograft (PDX) and ex-vivo tumor models for drug response testing in oncology, offering a functionally analogous (though slower) precision oncology testing service targeting the same oncologist and patient population as SageMedic.

3SEngine Precision Medicine
TypeEmerging player
Description

SEngine Precision Medicine runs ex-vivo functional drug screening on patient tumor samples to guide oncology treatment selection, making it one of the closest small-scale functional-profiling comparables to SAGE Oncotest.

TypeBroad incumbent
Description

Foundation Medicine is a leading genomic profiling company (FoundationOne CDx/FoundationOne Liquid CDx) widely used by oncologists for treatment decision support; it represents the incumbent standard-of-care approach that SageMedic positions its functional assay against.

5Tempus Labs
TypeBroad incumbent
Description

Tempus provides AI-enabled multi-modal precision oncology (genomic, transcriptomic, imaging) for oncologists and biopharma; it is a broad incumbent in cancer molecular profiling that competes for oncologist mindshare and ordering behavior.

TypeBroad incumbent
Description

Guardant Health offers liquid biopsy-based genomic profiling (Guardant360, Guardant Reveal) for advanced cancer treatment selection, addressing the same oncologist customer base and treatment-decision workflow as SageMedic.

TypeDirect peer
Description

Personalis provides tumor-informed molecular profiling (NeXT Personal) for oncology therapy selection and recurrence monitoring, competing for oncologist ordering and precision-oncology share of wallet in advanced solid tumors.

TypeBroad incumbent
Description

Natera is an established precision medicine company with oncology testing (Signatera) and a broader reproductive/oncology franchise; it competes for oncologist ordering and is a comparable reimbursement- and commercialization-driven diagnostics peer.

TypeEmerging player
Description

MI Bioresearch provides functional in-vitro and in-vivo oncology drug response testing services (including patient-derived models) for biopharma and clinical use, representing a niche functional-profiling peer with overlapping customer workflows.

TypeBroad incumbent
Description

Exact Sciences is a publicly-traded cancer diagnostics company (Cologuard, Oncotype) with a growing oncology menu; it is a broad incumbent competing for oncologist ordering and is a relevant comparable for a CLIA-certified cancer diagnostics commercial trajectory.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SageMedic

Functional Precision Oncology Diagnosticssagemedic.com

SageMedic Corp. operates a CLIA-certified laboratory offering the SAGE Oncotest™, an ex-vivo functional profiling assay that evaluates fresh tumor tissue against FDA-approved drugs to support oncologists' treatment decisions for Stage III/IV solid tumor patients on a self-pay basis.

What SageMedic does

SageMedic Corp. is a Redwood City, California-based CLIA-certified clinical laboratory (CLIA ID: 05D2236809, accredited by COLA and CMS) that develops and commercializes the SAGE Oncotest™, an ex-vivo functional profiling assay for solid tumor treatment decision support. The test processes fresh cancer tissue into multiple testable replicates within 24 hours and exposes those replicates to a curated panel of FDA-approved drugs, then returns laboratory drug response and resistance results to the ordering oncologist within 7-10 days. The company was founded in 2018 by Dr. Chris Apfel (CEO) and Dr. Brigitte Apfel (Co-Founder, Treasurer), both California-licensed physicians, and operates with 1-10 employees.

The product is positioned as a complement to genomic testing: whereas DNA sequencing identifies mutations, the SAGE Oncotest measures how the patient's actual tumor tissue responds to specific drugs ex-vivo, with internal validation claiming actionable laboratory information in 88% of cases compared to 26.8% for genomic testing and a meta-analysis-based claim that functional profiling makes tumors twice as likely to respond to therapy. The technology builds on published validation studies of predecessor ex-vivo Extreme Drug Resistance (EDR) assays with reported 90%+ negative predictive value. It is indicated for Stage III/IV solid tumors and is not used for early-stage or slow-growing cancers.

SageMedic generates revenue through a one-time, self-pay laboratory service fee per test; the test is not covered by insurance and pricing is not publicly disclosed. Distribution is B2B2C: physicians order the test, fresh tissue is collected at the surgical or biopsy facility and shipped to the California laboratory, and telemedicine consultations are offered only to patients physically in California at the time of service. Specimens are accepted from US physicians nationwide and from international hospitals and physicians, with consent and payment processed via DocuSign under a HIPAA Business Associate Agreement and patient screening handled through Zoho Forms.

SageMedic firmographics

Firmographics
Name
SageMedic
Legal name
SageMedic Corp.
Website
https://sagemedic.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
SageMedic Corp. operates a CLIA-certified laboratory offering the SAGE Oncotest™, an ex-vivo functional profiling assay that evaluates fresh tumor tissue against FDA-approved drugs to support oncologists' treatment decisions for Stage III/IV solid tumor patients on a self-pay basis.
Ownership category
akta.pro rank

SageMedic industry classification

Industry
Product category
Functional Precision Oncology Diagnostics
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAEAA
Central Laboratory Services (Core Lab Operations)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Functional cancer profiling
  • Precision oncology testing
  • Ex-vivo drug response
  • Tumor resistance profiling
  • CLIA laboratory services

Where SageMedic is headquartered

Location

Headquarters

HQ city
Redwood City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

SageMedic business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Others

Revenue model

  1. SAGE Oncotest Laboratory Testing: One-time laboratory testing service where patients pay for the test directly. The test is not covered by insurance. Physicians order the test, patients sign purchase agreements and pay for the service. Results are delivered within 7-10 days.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goLaboratory testing service - pricing not publicly disclosed

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

SageMedic product offering

Product offering

Core offering

SageMedic operates a CLIA-certified clinical laboratory offering the SAGE Oncotest™, an ex-vivo functional profiling assay that evaluates fresh cancer tissue samples against a curated panel of FDA-approved drugs to determine drug response and resistance patterns. Results are delivered to the ordering physician within 7-10 days to support individualized oncology treatment planning for patients with advanced solid tumors. Telemedicine consultations are also offered exclusively to patients physically located in California.

Product overview

SageMedic offers a single unified product, the SAGE Oncotest™ functional precision oncology test. This CLIA-certified laboratory service evaluates fresh tumor tissue samples against a curated panel of FDA-approved chemotherapy and targeted therapy drugs using proprietary ex-vivo laboratory techniques. The test is designed to complement genomic testing by providing functional drug response insights, helping oncologists make more informed treatment decisions for patients with advanced solid tumors. Results are delivered within 7-10 days.

Differentiator

Problem solved

Functional benefit

Brands

  • SAGE Oncotest™: Functional profiling assay that evaluates how a patient's tumor tissue responds to FDA-approved drug treatments ex-vivo, providing laboratory insights to support individualized cancer treatment planning within 7-10 days.

Quantifiable outcome

  • 88% actionable information rate vs 26.8% for genomic testing
  • +3 more outcomes

Companies that use SageMedic

Customer profile

Segments3 records

Ideal customer profiles2 records

SageMedic technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

Feature4 records

SageMedic partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

SageMedic competitors and assessment

Company assessment

Direct peers

  • Caris Life Sciences: Caris offers multi-omic molecular profiling (DNA, RNA, protein) for oncology, including functional and proteomic components, serving oncologists with treatment-decision support — directly comparable to SageMedic's functional profiling service for advanced solid tumors.
  • Champions Oncology: Champions provides patient-derived xenograft (PDX) and ex-vivo tumor models for drug response testing in oncology, offering a functionally analogous (though slower) precision oncology testing service targeting the same oncologist and patient population as SageMedic.
  • Personalis: Personalis provides tumor-informed molecular profiling (NeXT Personal) for oncology therapy selection and recurrence monitoring, competing for oncologist ordering and precision-oncology share of wallet in advanced solid tumors.

Emerging players

  • SEngine Precision Medicine: SEngine Precision Medicine runs ex-vivo functional drug screening on patient tumor samples to guide oncology treatment selection, making it one of the closest small-scale functional-profiling comparables to SAGE Oncotest.
  • MI Bioresearch (part of Molecular Imaging): MI Bioresearch provides functional in-vitro and in-vivo oncology drug response testing services (including patient-derived models) for biopharma and clinical use, representing a niche functional-profiling peer with overlapping customer workflows.

Broad incumbents

  • Foundation Medicine: Foundation Medicine is a leading genomic profiling company (FoundationOne CDx/FoundationOne Liquid CDx) widely used by oncologists for treatment decision support; it represents the incumbent standard-of-care approach that SageMedic positions its functional assay against.
  • Tempus Labs: Tempus provides AI-enabled multi-modal precision oncology (genomic, transcriptomic, imaging) for oncologists and biopharma; it is a broad incumbent in cancer molecular profiling that competes for oncologist mindshare and ordering behavior.
  • Guardant Health: Guardant Health offers liquid biopsy-based genomic profiling (Guardant360, Guardant Reveal) for advanced cancer treatment selection, addressing the same oncologist customer base and treatment-decision workflow as SageMedic.
  • Natera: Natera is an established precision medicine company with oncology testing (Signatera) and a broader reproductive/oncology franchise; it competes for oncologist ordering and is a comparable reimbursement- and commercialization-driven diagnostics peer.
  • Exact Sciences: Exact Sciences is a publicly-traded cancer diagnostics company (Cologuard, Oncotype) with a growing oncology menu; it is a broad incumbent competing for oncologist ordering and is a relevant comparable for a CLIA-certified cancer diagnostics commercial trajectory.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

SageMedic compliance and trust

Trust signal

Compliance2 records

SageMedic financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SageMedic leadership team

Management profile

Number of profiles

Profiles14 records

SageMedic funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SageMedic M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SageMedic

What does SageMedic do?

SageMedic operates a CLIA-certified clinical laboratory offering the SAGE Oncotest™, an ex-vivo functional profiling assay that evaluates fresh cancer tissue samples against a curated panel of FDA-approved drugs to determine drug response and resistance patterns. Results are delivered to the ordering physician within 7-10 days to support individualized oncology treatment planning for patients with advanced solid tumors. Telemedicine consultations are also offered exclusively to patients physically located in California.

Is SageMedic a public or private company?

SageMedic is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was SageMedic founded?

SageMedic was founded in 2018. It employs 11 to 50 people.

Where is SageMedic based?

SageMedic is headquartered in Redwood City, United States, in the North America region.

How does SageMedic make money?

One revenue line is on record: SAGE Oncotest Laboratory Testing.

Who are SageMedic's main competitors?

Direct peers on record are Caris Life Sciences, Champions Oncology and Personalis. Emerging players are SEngine Precision Medicine and MI Bioresearch (part of Molecular Imaging). Broad incumbents are Foundation Medicine, Tempus Labs, Guardant Health, Natera and Exact Sciences.

Does SageMedic have an API?

No public API is recorded for SageMedic.

What industry is SageMedic in?

SageMedic's product category is Functional Precision Oncology Diagnostics. Its primary akta.pro industry code is HLAGAEAA, Central Laboratory Services (Core Lab Operations), with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals